Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
S. Camillo Hospital, Monopoli, Bari, Italy.
G Ital Dermatol Venereol. 2020 Oct;155(5):622-631. doi: 10.23736/S0392-0488.19.06399-5.
Androgenetic alopecia (AGA) is the most common form of alopecia, affecting up to 80% of men and 50% of women in the course of their life. AGA is caused by a progressive reduction in the diameter, length and pigmentation of the hair, resulting from the effects of the testosterone metabolite dihydrotestosterone (DHT) on androgen-sensitive hair follicles. Clinical presentation is different in men and women. Trichoscopy is used routinely in patients with androgenetic alopecia, for diagnosis and differential diagnosis with other diseases, allowing staging of severity and monitoring the progress of the disease and the response to treatment. Medical treatment of AGA includes topical minoxidil, antiandrogen agents, 5-alpha reductase inhibitors and many other options. This guideline for the treatment of androgenetic alopecia has been developed by an Italian group of experts taking into account the Italian pharmacological governance. The article is adapted from the original of the European Dermatology Forum (EDF) in collaboration with the European Academy of Dermatology and Venereology (EADV). It summarizes evidence-based and expert-based recommendations (S3 level).
雄激素性脱发（AGA）是最常见的脱发类型，在其一生中，多达 80%的男性和 50%的女性受到影响。AGA 是由于睾酮代谢物二氢睾酮（DHT）对雄激素敏感的毛囊的作用，导致头发直径、长度和色素沉着逐渐减少所致。男性和女性的临床表现不同。毛发镜检查在雄激素性脱发患者中常规使用，用于诊断和与其他疾病进行鉴别诊断，可对严重程度进行分期，监测疾病进展和治疗反应。AGA 的药物治疗包括局部米诺地尔、抗雄激素药物、5-α 还原酶抑制剂和许多其他选择。本 AGA 治疗指南由意大利专家组制定，考虑到了意大利的药理学管理。本文改编自欧洲皮肤病学论坛（EDF）与欧洲皮肤病学会和性病学会（EADV）合作的原始版本。它总结了基于证据和专家的建议（S3 级）。
